linjc16/ctgov huggingface dataset:
Relationship of Endoplasmic Reticulum Stress and Adenoid Diseases

Study Overview
=================
Brief Summary
-----------------
Adenoid tissue is a significant organ for the performing of immune systems in children. The Endoplasmic Reticulum (ER), is an organelle needed for the care of a stable function of cells. The purpose of the study was to explore the correlation among ER stress and adenoid tissue disorders and to explain the structure of diseases related to the immune system.

Official Title
-----------------
Relationship Between Apoptosis and er Stress in Chronic Adenoiditis and Adenoid Hypertrophy

Conditions
-----------------
Adenoiditis Acute Infective

Intervention / Treatment
-----------------
* Procedure: Adenoidectomy surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Patients with the clinical diagnosis of chronic adenoiditis and adenoid hypertrophy. Exclusion Criteria: Systemic diseases Other otolaryngological

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 9 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Chronic adenoiditis<br>Patients with hypertrophy and those out of hypertrophy were determined and those who had purulant rhinorrhea signs and rate of adenoids-choana below 50% were categorized that chronic adenoiditis. | Procedure: Adenoidectomy surgery<br>* All patients underwent adenoidectomy under general anesthesia by routine curettage method and adenoid tissues were put in formaldehyde and sent to the genetics department for the exploration of ER stress and apoptosis markers.<br>|
| Adenoid hypertrophy<br>Patients who have snoring and those whose adenoid choana rate is greater than 50% were categorized that adenoid hypertrophy group. | Procedure: Adenoidectomy surgery<br>* All patients underwent adenoidectomy under general anesthesia by routine curettage method and adenoid tissues were put in formaldehyde and sent to the genetics department for the exploration of ER stress and apoptosis markers.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of ER stress and apoptosis with chronic adenoiditis and adenoid hypertrophy | Our primary outcome was to evaluate providing that ER stress and apoptosis reaction performing in chronic adenoiditis and adenoid hypertropy, which is related with the immune system of children. | 2018-2019 (1 year) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Adenoidectomy, ; Endoplasmic Reticulum
Different Types of Suture for Sacral Colpopexy

Study Overview
=================
Brief Summary
-----------------
This randomized controlled study is designed to test absorbable suture compared to non absorbable suture in laparoscopic sacral colpopexy in terms of anatomical correction of the prolapse, post-operative and long term morbidity, rate of recurrence, subjective satisfaction of the patient and rate of mesh erosion.

Official Title
-----------------
Absorbable vs Non-absorbable Suture in Laparoscopic Sacral Colpopexy: a Randomized Controlled Trial

Conditions
-----------------
Pelvic Organ Prolapse

Intervention / Treatment
-----------------
* Procedure: laparoscopic sacral colpopexy with absorbable suture
* Procedure: laparoscopic sacral colpopexy with non absorbable suture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who required surgical treatment for symptomatic pelvic organ prolapse stage ≥ 2 with or without stress urinary incontinence Exclusion Criteria: Age > 75 years Severe cardiovascular or respiratory disease Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Absorbable suture<br>laparoscopic sacral colpopexy with absorbable suture | Procedure: laparoscopic sacral colpopexy with absorbable suture<br>* laparoscopic sacral colpopexy to correct pelvic organ prolapse with anterior and posterior meshes with absorbable suture<br>|
| Active Comparator: Non absorbable suture<br>laparoscopic sacral colpopexy with non absorbable suture | Procedure: laparoscopic sacral colpopexy with non absorbable suture<br>* laparoscopic sacral colpopexy to correct pelvic organ prolapse with anterior and posterior meshes with non absorbable suture<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with anatomical correction of the prolapse | Anatomical correction of the prolapse evaluated by gynecological visit | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rate mesh erosion |  | 1 year | 
| long term outcomes | development of nicturia, dysuria, obstructed defecation , urinary incontinence | 1 year | 
| Rate of recurrence | de novo anterior or central or posterior compartment prolapse | 1 year |
Lavender During Intrauterine Insemination

Study Overview
=================
Brief Summary
-----------------
The Researchers hope to learn if by using lavender aromatherapy during an intrauterine insemination patients have decreased anxiety and pain at the time of the procedure.

Detailed Description
-----------------
Infertility patients have a high level of anxiety before and during infertility treatments due to anticipated discomfort of a procedure and anticipation of a long awaited pregnancy. Aromatherapy with lavender, an essential oil, has been shown to be effective in reducing anxiety and pain in a variety of procedures such as Botox injections, cesarean delivery and intrauterine device placement.

Official Title
-----------------
Lavender Aromatherapy vs Placebo to Decrease Anxiety and Pain During Intrauterine Insemination (IUI).

Conditions
-----------------
Anxiety, Infertility, Female

Intervention / Treatment
-----------------
* Other: Lavender
* Other: Water


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women undergoing intrauterine insemination English speaking Exclusion Criteria: Allergy to lavender oil or its components Currently using aromatherapy Contraindication to intrauterine insemination Contraindication to pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Lavender<br>Lavandula angustifolia aromatherapy. 1 drop on a cotton ball placed in a porous pouch. Given to patients at the time of their intrauterine insemination. | Other: Lavender<br>* Lavender aromatherapy<br>* Other names: Lavandula angustifolia;|
| Placebo Comparator: Water<br>1 drop of water on a cotton ball placed in a porous pouch. Given to patients at the time of their intrauterine insemination. | Other: Water<br>* Water<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anxiety | Anxiety level using a standard visual analog scale. Scale is from 0-100 mm. 0 is absent anxiety. 100 mm is maximal anxiety. | During intrauterine insemination procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain | Pain score using Wong-Baker pain scale of 0-10. 0 being absent pain and 10 being maximal pain. | During intrauterine insemination procedure |
Cardiogenic Shock Registry Mannheim

Study Overview
=================
Brief Summary
-----------------
The study aims to investigate clinically and prognostically relevant parameters in patients with cardiogenic shock within a monocentric observational clinical register.

Detailed Description
-----------------
All consecutive patients with a confirmed cardiogenic shock presenting at the internal intensive care Unit (ICU) at the University of Mannheim are included in the register and followed up during ICU stay and after that. Data of patients' admission status, cause of cardiogenic shock, baseline parameters and comorbidities are collected. Extensive information about echocardiography, electrocardiography and imaging procedures are included in the register. Laboratory values, microbiological investigations, organ dysfunction and organ replacement therapies, medication, adverse events, and complications were recorded for several days during the ICU stay (days 1, 2, 3, 5, 7, and 8). Standard scores for critically ill patients were calculated for the day of admission at the ICU if available, and several time points during the ICU stay. The register includes information about the mortality during ICU stay, 30-day mortality, 6-month mortality and 1-year mortality.

Official Title
-----------------
Cardiogenic Shock Registry Mannheim - CARESMA

Conditions
-----------------
Cardiogenic Shock

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cardiogenic shock according to current guidelines Exclusion Criteria: other forms of shock not primary associated with cardiac dysfunction

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all-cause mortality | days | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| all-cause mortality | during hospital stay (up to 30 days) | during hospital stay (up to 30 days) | 
| all-cause mortality | years | 1 years | 
| ventilator-free days | days | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cardiogenic shock, heart failure, cardiac arrest, shock, acute myocardial infarction
Shear Wave Elastography of Rectal Adenomas and Cancer

Study Overview
=================
Brief Summary
-----------------
The diagnosis of rectal lesions is a challenging task, and the accuracy of the primary staging is important preoperatively. A relatively novel technology makes it possible to measure the tissue stiffness during endorectal ultrasonography. The purpose of this study is to evaluate the diagnostic value of Shear Wave Elastography (SWE). The hypothesis is that the tissue stiffness is higher in malignant tissue than in benign lesions.

Detailed Description
-----------------
This study will include patients with an endoscopy verified rectal lesion referred to the radiology department for pretreatment evaluation. During the investigation, patients will undergo magnetic resonance imaging (MRI) and endorectal ultrasonography (ERUS). During the ERUS, the tissue stiffness of the lesion and visible lymph nodes will be measured using the SWE technology. Hypotheses: Tumour stiffness measurement by SWE gives a statistically significantly higher value in malignant processes than in benign rectal tumors. Tissue stiffness measurement with SWE gives a statistically significantly higher value in lymph node metastases than in reactive enlarged lymph nodes. There is a statistically significant correlation between SWE and MRI apparent diffusion coefficient (ADC) Histopathology report of surgical specimen will serve as endpoint.

Official Title
-----------------
Shear Wave Elastography of Rectal Adenomas and Cancer

Conditions
-----------------
Rectal Neoplasms, Elasticity Imaging Techniques

Intervention / Treatment
-----------------
* Diagnostic Test: Shear Wave Elastography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adults above 18 years of age Rectal lesions discovered during endoscopy Lesions located no more than 15 cm above the anal verge Exclusion Criteria: Non-eligibility for MRI (e.g. claustrophobia, implants) Preoperative radiotherapy and/or chemotherapy
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Shear Wave Elastography<br>SWE value measurement will be added during the ERUS examination. | Diagnostic Test: Shear Wave Elastography<br>* SWE value of rectal lesions<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SWE accuracy | The accuracy of SWE value as compared with the histopathology report | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SWE and ADC measurement | The correlation between ERUS SWE and MRI ADC value | 1 week |
Effect of Flamingo Exercises on Balance

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to determine the effect of flamingo exercise on balance in patients with balance impairment due to senil osteoarthritis

Detailed Description
-----------------
Changes in the sensory, neurological, and musculoskeletal systems in older adults affect several motor tasks,including postural balance. Also osteoarthritis contribute to this process. Older people can gain balance disorders. The flamingo balance exercise is a full lower body workout utilizing many major muscle groups. Therefore investigators aimed to determine the effect of flamingo exercise combined with kinesthetic ability trainer or alone in patients with balance impairment due to osteoarthritis

Official Title
-----------------
Effect of Flamingo Exercises on Balance in Patients With Balance Impairment Due to Senile Osteoarthritis

Conditions
-----------------
Osteoarthritis, Gait Disorders, Neurologic

Intervention / Treatment
-----------------
* Other: Flamingo exercise
* Other: training with kinesthetic ability trainer


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Older than 65 years old osteoarthritis diagnosis Balance impairment (Berg balance scale 21-40 points) Exclusion Criteria: Severe neurological deficit Defect of vision Vitamin B12 deficiency Sedative drug use

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group 1<br>training with kinesthetic ability trainer. | Other: training with kinesthetic ability trainer<br>* training with kinesthetic ability trainer<br>|
| Active Comparator: Group 2<br>Flamingo exercise | Other: Flamingo exercise<br>* Flamingo exercise<br>|
| Active Comparator: Group 3<br>training with kinesthetic ability trainer and Flamingo exercise | Other: Flamingo exercise<br>* Flamingo exercise<br>Other: training with kinesthetic ability trainer<br>* training with kinesthetic ability trainer<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| kinesthetic ability trainer static score | kinesthetic ability trainer static score | 4 weeks | 
| kinesthetic ability trainer static dynamic score | kinesthetic ability trainer static dynamic score | 4 weeks | 
| Berg Balance Scale | a scale for balance | 4 weeks | 
| Timed up and Go test | for balance and gait | 4 weeks | 
| activity specific balance scale. | for balance | 4 weeks |
The Contemporary Role of Beta Blockers in Patients With Acute Myocardial Infarction

Study Overview
=================
Brief Summary
-----------------
The use of beta blockers after acute myocardial infarction is a core component of drug therapy, but evidence is primarily derived from patients who did not receive reperfusion therapy and secondary prophylaxis.In contemporary times, the prognostic value of beta blockers in patients with acute myocardial infarction has been questioned, particularly in patients without reduced heart failure/ejection fraction after acute myocardial infarction.

Official Title
-----------------
Influence of Beta-Blockers on Prognosis in Patients With Acute Myocardial Infarction Complicated With Normal Ejection Fraction

Conditions
-----------------
Acute Coronary Syndrome

Intervention / Treatment
-----------------
* Drug: beta-blocker


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The diagnosis of acute myocardial infarction was clear and the left ventricular ejection fraction was normal Exclusion Criteria: History of heart failure Died in hospital

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| with beta-blocker<br> | Drug: beta-blocker<br>* To investigate the relationship between the use of beta blockers and prognosis in patients with normal ejection fraction after acute myocardial infarction<br>|
| without beta-blocker<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mortality | all-cause mortality | the median time of 8 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
left ventricular ejection fraction, acute myocardial infarction, beta-blocker
Regional Fatty Acid Metabolism in Humans

Study Overview
=================
Brief Summary
-----------------
There are several studies looking at how dietary fat is metabolized by humans. We give special meals and collect blood, breath, urine and fat samples to study how people burn and store dietary fat.

Official Title
-----------------
Regional Fatty Acid Metabolism in Humans

Conditions
-----------------
Diabetes Mellitus, Type 2

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI<25 Lean, sedentary with family history of DM2 and Lean, sedentary without family history of DM2 and Lean, active without family history of DM2. Non-smokers. Exclusion Criteria: Known systemic illness, cardiac and vascular disease and BP> 160/95 on HTN meds. Medications that affect fat metabolism. We do not pay for travel expenses.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
type 2 diabetes, some studies - family history of type 2 diabetes
Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate Background

Study Overview
=================
Brief Summary
-----------------
The purpose of this clinical research study is to learn if it is safe for rheumatoid arthritis patients to take BMS-582949 along with methotrexate.

Official Title
-----------------
Multiple Ascending Dose Study of BMS-582949 in Patients With Stable Rheumatoid Arthritis on the Methotrexate Background

Conditions
-----------------
Rheumatoid Arthritis

Intervention / Treatment
-----------------
* Drug: BMS-582949 and Methotrexate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-70 years Diagnosis of RA for ≥6 months Swollen or tender joint or ESR >ULN. Subject must be on stable doses of MTX Women of Childbearing Potential Exclusion Criteria: Serum transaminase levels >ULN CK>ULN Cannot have taken Orencia or Remicade within 8 weeks of baseline, Humira or Enbrel within 4 weeks of baseline Use of H2 blockers or Proton Pump inhibitors while on study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: BMS-582949 and Methotrexate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate safety and tolerability of BMS-582949 in subjects with active rheumatoid arthritis receiving concomitant MTX at steady state |  | during 28 doses of treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the PK of BMS-582949 in clinically stable RA subjects on stable doses of MTX and concomitant BMS-582949 |  |  | 
| To explore DAS28, ESR, RF and CRP of clinically stable doses of MTX and concomitant BMS-582949 compared to MTX alone |  | during 28 days of treatment | 
| To evaluate PK of MTX in stable RA subjects in the absence and presence of BMS-582949 for subjects enrolled prior to approval of amendment 2 |  |  |